The FDA approves Spectrum Pharmaceuticals’ (NASDAQ:SPPI) folate analog KHAPZORY (levoleucovorin) for injection for the treatment of patients with metastatic colorectal cancer in combination with fluorouracil, for diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination and for rescue after high-dose methotrexate therapy in osteosarcoma patients.
The company says it is evaluating strategic options on commercial launch and expects product availability in January.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.